| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
47,262,000 |
| Market
Cap: |
12.96(B) |
| Last
Volume: |
329,299 |
Avg
Vol: |
421,496 |
| 52
Week Range: |
$205.19 - $272.69 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile United Therapeutics is a biotechnology company. Through its subsidiary, Lung Biotechnology PBC, Co. is focused on addressing the acute national shortage of transplantable lungs and other organs with a variety of technologies that either delay the need for such organs or expand the supply. Co. markets and sells the following commercial therapies to treat pulmonary arterial hypertension: Remodulin® (treprostinil) Injection; Tyvaso® (treprostinil) Inhalation Solution; Orenitram® (treprostinil) Extended-Release Tablets; and Adcirca® (tadalafil) Tablets. In the U.S., Co. also markets and sells an oncology product, Unituxin® (dinutuximab) Injection, for the treatment of high-risk neuroblastoma.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
561,075 |
601,080 |
663,963 |
1,859,458 |
| Total Sell Value |
$136,150,891 |
$145,221,114 |
$159,349,326 |
$455,394,009 |
| Total People Sold |
8 |
8 |
8 |
11 |
| Total Sell Transactions |
65 |
74 |
86 |
265 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2022-11-17 |
4 |
AS |
$258.21 |
$2,089,392 |
D/D |
(8,000) |
130 |
|
-15% |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2022-11-17 |
4 |
OE |
$113.08 |
$904,640 |
D/D |
8,000 |
8,130 |
|
- |
|
| Patusky Christopher |
|
– • – |
2022-11-17 |
4 |
AS |
$262.61 |
$26,261 |
I/I |
(100) |
1,100 |
|
-15% |
|
| Mahon Paul A |
EVP & GENERAL COUNSEL |
• – – |
2022-11-17 |
4 |
AS |
$257.93 |
$1,554,296 |
D/D |
(6,000) |
36,397 |
|
-15% |
|
| Mahon Paul A |
EVP & GENERAL COUNSEL |
• – – |
2022-11-17 |
4 |
OE |
$120.26 |
$721,560 |
D/D |
6,000 |
42,397 |
|
- |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2022-11-16 |
4 |
AS |
$260.48 |
$2,094,902 |
D/D |
(8,000) |
130 |
|
-16% |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2022-11-16 |
4 |
OE |
$113.08 |
$904,640 |
D/D |
8,000 |
8,130 |
|
- |
|
| Patusky Christopher |
|
– • – |
2022-11-16 |
4 |
D |
$261.05 |
$391,575 |
D/D |
(1,500) |
1,680 |
|
- |
|
| Patusky Christopher |
|
– • – |
2022-11-16 |
4 |
OE |
$88.03 |
$132,045 |
D/D |
1,500 |
3,180 |
|
- |
|
| Giltner Richard |
|
– • – |
2022-11-16 |
4 |
D |
$261.05 |
$2,610,500 |
D/D |
(10,000) |
13,870 |
|
- |
|
| Giltner Richard |
|
– • – |
2022-11-16 |
4 |
OE |
$63.90 |
$639,000 |
D/D |
10,000 |
23,870 |
|
- |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2022-11-15 |
4 |
AS |
$255.91 |
$2,065,993 |
D/D |
(8,000) |
130 |
|
-16% |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2022-11-15 |
4 |
OE |
$113.08 |
$904,640 |
D/D |
8,000 |
8,130 |
|
- |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2022-11-14 |
4 |
AS |
$255.25 |
$2,065,338 |
D/D |
(8,000) |
130 |
|
-14% |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2022-11-14 |
4 |
OE |
$113.08 |
$904,640 |
D/D |
8,000 |
8,130 |
|
- |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2022-11-11 |
4 |
AS |
$251.99 |
$2,044,785 |
D/D |
(8,000) |
130 |
|
-15% |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2022-11-11 |
4 |
OE |
$113.08 |
$904,640 |
D/D |
8,000 |
8,130 |
|
- |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2022-11-10 |
4 |
AS |
$257.73 |
$2,092,043 |
D/D |
(8,000) |
130 |
|
-16% |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2022-11-10 |
4 |
OE |
$113.08 |
$904,640 |
D/D |
8,000 |
8,130 |
|
- |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2022-11-09 |
4 |
AS |
$262.09 |
$2,115,602 |
D/D |
(8,000) |
130 |
|
-18% |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2022-11-09 |
4 |
OE |
$113.08 |
$904,640 |
D/D |
8,000 |
8,130 |
|
- |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2022-11-09 |
4 |
AS |
$263.93 |
$84,456 |
D/D |
(320) |
524 |
|
-18% |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2022-11-08 |
4 |
AS |
$261.21 |
$2,017,508 |
D/D |
(7,680) |
130 |
|
-19% |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2022-11-08 |
4 |
OE |
$113.08 |
$904,640 |
D/D |
8,000 |
8,130 |
|
- |
|
| Olian Judy D. |
|
– • – |
2022-11-08 |
4 |
S |
$265.09 |
$159,054 |
D/D |
(600) |
8,665 |
|
19% |
|
2674 Records found
|
|
Page 19 of 107 |
|
|
2.04 (0.75%) 
